U.S. markets open in 57 minutes

Cortexyme, Inc. (CRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
37.99+1.62 (+4.45%)
At close: 4:00PM EST

37.99 0.00 (0.00%)
Pre-Market: 8:00AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
Previous Close36.37
Open36.54
Bid26.30 x 800
Ask42.00 x 800
Day's Range33.58 - 38.11
52 Week Range26.66 - 58.99
Volume282,707
Avg. Volume331,185
Market Cap1.123B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.63
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation
    Business Wire

    Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, announced that it has partnered with the Parkinson Study Group (PSG) to form an Advisory Board to leverage the group’s expertise and further develop the company’s Parkinson’s disease (PD) program. In addition, Cortexyme will present new data further demonstrating the role of Porphyromonas gingivalis (P. gingivalis) in the development of Alzheimer’s disease at AD/PD™ 2021, the 15th International Conference on Alzheimer’s & Parkinson’s Diseases, which is being held virtually March 9-14, 2021.

  • Newsfile

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

    New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining ...

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Cortexyme, Inc. (CRTX) Investigation

    NEW YORK, NY / ACCESSWIRE / February 18, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cortexyme, Inc. ("Cortexyme" or "the Company") (NASDAQ:CRTX).